發(fā)布時(shí)間：2018-03-10 00:03

  本文選題：重組人血管內(nèi)皮抑素　切入點(diǎn)：心臟毒性　出處：《新疆醫(yī)科大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：探討恩度(重組人血管內(nèi)皮抑素)對(duì)中晚期非小細(xì)胞肺癌(NSCLC)患者的心臟毒性及其相關(guān)危險(xiǎn)因素。方法：選擇188例既往無嚴(yán)重心血管病史、經(jīng)病理組織學(xué)或細(xì)胞學(xué)確診為中晚期失去手術(shù)機(jī)會(huì)的NSCLC化療患者,其中92例經(jīng)多西他賽+奈達(dá)鉑+恩度治療(試驗(yàn)組),96例經(jīng)多西他賽+奈達(dá)鉑治療(對(duì)照組),兩組一般臨床資料差異無統(tǒng)計(jì)學(xué)意義(P0.05)。每一化療周期為21天,至少完成2個(gè)周期�；熎陂g監(jiān)測(cè)兩組患者的血壓及心電圖,并記錄患者心血管系統(tǒng)癥狀,陽性者測(cè)定心肌酶譜和肌鈣蛋白-T。結(jié)果：兩組比較,化療后試驗(yàn)組與對(duì)照組的心臟毒性差異有統(tǒng)計(jì)學(xué)意義(P0.05)。同組比較,試驗(yàn)組化療前后心臟毒性差異有統(tǒng)計(jì)學(xué)意義(P0.05),且第1周期與第2期化療后心電圖改變差異有統(tǒng)計(jì)學(xué)意義(P0.05),其中8例(8.6%)患者出現(xiàn)了心肌酶的改變；對(duì)照組化療前后心臟毒性差異無統(tǒng)計(jì)學(xué)意義(P0.05)。試驗(yàn)組心臟毒性反應(yīng)的發(fā)生率從高到底依次為心電圖改變、心血管系統(tǒng)癥狀和血壓改變,經(jīng)logistic回歸分析表明,年齡大小、既往有無心血管病史對(duì)恩度心臟毒性的影響差異有統(tǒng)計(jì)學(xué)意義(均P0.05),民族、腫瘤臨床分期、有無糖尿病病史對(duì)恩度心臟毒性的影響差異無統(tǒng)計(jì)學(xué)意義(均P0.05)。結(jié)論：恩度的心臟毒性主要表現(xiàn)為心電圖改變、心血管系統(tǒng)癥狀和血壓改變,其中心電圖異常最常見,高齡、既往有心血管病史是恩度心臟毒性的危險(xiǎn)因素。
[Abstract]:Objective: to investigate the cardiotoxicity of Endox (recombinant human vascular endostatin) in patients with advanced non-small cell lung cancer (NSCLC) and its risk factors. NSCLC chemotherapy patients who were diagnosed by histopathology or cytology as losing surgical opportunity in the middle and late stage, Among them, 92 cases were treated with docetanideplatin (trial group, 96 cases were treated with docetanideplatin) (control group, there was no significant difference in general clinical data between the two groups (P 0.05). Each chemotherapy period was 21 days. At least 2 cycles were completed. Blood pressure and electrocardiogram were monitored during chemotherapy in both groups, and cardiovascular system symptoms were recorded. Myocardial enzyme spectrum and troponin T.Results: the two groups were compared. There was significant difference in cardiac toxicity between the experimental group and the control group after chemotherapy. There were significant differences in cardiac toxicity before and after chemotherapy in the trial group (P 0.05), and there were significant differences in electrocardiogram between the first cycle and the second stage of chemotherapy. There was no significant difference in cardiac toxicity before and after chemotherapy in the control group (P 0.05). The incidence of cardiac toxicity in the experimental group was in the order of electrocardiogram changes, cardiovascular system symptoms and blood pressure changes. Logistic regression analysis showed that age was large and small. There were significant differences in the influence of cardiovascular history on the cardiac toxicity of Endor (all P 0.05, nationality, tumor clinical stage, P 0.05). There was no significant difference in the effects of diabetic history on Endor's cardiac toxicity (all P 0.05). Conclusion: the main manifestations of cardiac toxicity of Endor are electrocardiogram changes, cardiovascular system symptoms and blood pressure changes, among which abnormal ECG is the most common, and elderly. A previous history of cardiovascular disease is a risk factor for Endor's cardiac toxicity.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 沈春燕;佟仲生;穆海玉;;恩度聯(lián)合含鉑類化療方案治療晚期非小細(xì)胞肺癌的臨床觀察[J];天津醫(yī)科大學(xué)學(xué)報(bào);2010年02期

2 王志東;田曉彩;劉蒸生;韓有健;梁峰翎;;恩度聯(lián)合化療一線治療老年晚期肺鱗癌的臨床研究[J];中國(guó)當(dāng)代醫(yī)藥;2012年19期

，

本文編號(hào)：1590848